How to cite item

High density lipoprotein 3 inhibits oxidized low density lipoprotein-induced apoptosis via promoting cholesterol efflux in RAW264.7 cells

  
@article{APS3744,
	author = {Pei Jiang and Peng-ke Yan and Jian-xiong Chen and Bing-yang Zhu and Xiao-yong Lei and Wei-dong Yin and Duan-fang Liao},
	title = {High density lipoprotein 3 inhibits oxidized low density lipoprotein-induced apoptosis via promoting cholesterol efflux in RAW264.7 cells},
	journal = {Acta Pharmacologica Sinica},
	volume = {27},
	number = {2},
	year = {2016},
	keywords = {},
	abstract = {Aim: To investigate the protective effect of high density lipoprotein 3 (HDL3) on
oxidized low density lipoprotein (ox-LDL)-induced apoptosis in RAW264.7 cells.
Methods: RAW264.7 cells were exposed to 50 mg/L ox-LDL for various durations
up to 48 h, and apoptosis was detected using Hoechst 33258 staining and flow
cytometric analysis. Total cholesterol levels were detected by high performance
liquid chromatography, cholesterol efflux was determined by Tritium labeling, and
the cellular lipid droplets were assayed by oil red O staining. Results: Treatment
with 50 mg/L ox-LDL for 12, 24, and 48 h increased the apoptotic rate of RAW264.
7 cells in a time-dependent manner. The peak apoptotic rate (47.7%) was observed
after 48 h incubation. HDL3 at various concentrations (50 mg/L, 100 mg/L, and 200
mg/L) inhibited the ox-LDL (50 mg/L for 48 h)-mediated apoptosis that was accompanied
by an increased rate of intracellular cholesterol efflux, and decreased total
cholesterol levels in cells in a concentration-dependent manner. Blockage of
cholesterol efflux by brefeldin decreased the protective effect of HDL3 on ox-LDLinduced
apoptosis. Increase of the cholesterol efflux effected by another cholesterol
acceptor, β-cyclodextrin, led to a dramatic decrease in the apoptotic rate of
cells. Conclusion: HDL3 antagonizes ox-LDL-induced apoptosis in RAW264.7
cells, through reducing the accumulation of toxic cholesterol.},
	issn = {1745-7254},	url = {http://www.chinaphar.com/article/view/3744}
}